<i>In vitro</i> modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant <i>EGFR</i> mutants in non-small-cell lung cancerToshiyuki Hirano, Kenzo Soejima, Hiroyuki Yasuda et al.|Oncotarget|2015Cited by 159
Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung CancerMasayoshi Miyawaki, Kenzo Soejima, Hiroyuki Yasuda et al.|Molecular Cancer Research|2016Cited by 73
Activation of EGFR Bypass Signaling by TGFα Overexpression Induces Acquired Resistance to Alectinib in <i>ALK</i> -Translocated Lung Cancer CellsTetsuo Tani, Kenzo Soejima, Hiroyuki Yasuda et al.|Molecular Cancer Therapeutics|2015Cited by 63
Erlotinib as second- or third-line treatment in elderly patients with advanced non-small cell lung cancer: Keio Lung Oncology Group Study 001 (KLOG001)Masayoshi Miyawaki, Kenzo Soejima, Katsuhiko Naoki et al.|Molecular and Clinical Oncology|2017Cited by 10
Social impact of brain fog and analysis of risk factors: Long <scp>COVID</scp> in Japanese populationLisa Shigematsu, Koichi Fukunaga, Takanori Asakura et al.|Annals of Clinical and Translational Neurology|2024Cited by 9